News
04-28-2011, 07:01 AM
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.
More... (http://www.news-medical.net/news/20110428/FDA-accepts-OncoMeds-IND-filing-for-OMP-18R5-in-Phase-1-clinical-trial-for-advanced-solid-tumors.aspx)
More... (http://www.news-medical.net/news/20110428/FDA-accepts-OncoMeds-IND-filing-for-OMP-18R5-in-Phase-1-clinical-trial-for-advanced-solid-tumors.aspx)